Genetics
60 articles on Genetics, researched and written by the Shotlee Editorial Team from primary sources.
Truth About Mounjaro Jowls: Rosie O'Donnell's Facelift That Can't Hide Weight Loss
Rapid weight loss on GLP-1 medications often leads to skin laxity because the body loses subcutaneous fat faster than collagen and elastin can regenerate. This biological lag creates visible sagging, particularly in areas with high elasticity like the jawline and neck.
6 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell discusses her 30kg weight loss using Mounjaro, the subsequent skin concerns, and the mental health benefits of GLP-1 therapy.
6 min read
Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging
A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.
8 min read
Ozempic and Similar Weight-Loss Medications Linked to 30% Lower Breast Cancer Risk
A major study from Penn Medicine reveals a potential link between GLP-1 medications like Ozempic and a significant reduction in breast cancer risk, offering new hope for preventive care.
7 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Beyond the Hype: Why Some Aren't Responding to GLP-1 Weight Loss Drugs
While GLP-1 agonists have revolutionized weight loss for many, a significant portion of individuals don't experience the same dramatic results. This article delves into the reasons behind GLP-1 non-response and offers guidance for those seeking effective weight management solutions.
7 min read
Wegovy for Children: Safety Concerns, Obesity Trends, and Expert Advice
An in-depth look at the controversial use of GLP-1 medications in pediatric patients, childhood obesity statistics, and long-term safety concerns highlighted by medical experts.
8 min read
Beyond Ozempic: Exploring the Expanding World of Peptide Therapeutics
Peptides are making waves in health and wellness, driven by the success of medications like Ozempic. This article delves into what peptides are, their growing applications, and the exciting future of peptide therapy.
8 min read
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
8 min read
GLP-1 Drugs: A New Frontier in Addiction Treatment?
Could the same medications revolutionizing weight loss and diabetes management also hold the key to treating addiction? Emerging research suggests GLP-1 receptor agonists may play a significant role.
8 min read
Michelle Obama's Weight: Addressing Speculation and GLP-1 Rumors
Recent public appearances by Michelle Obama have sparked widespread discussion about her appearance and weight. This article delves into the speculation, explores the role of GLP-1 medications in weight management, and discusses the broader implications of public observation on health and wellness.
6 min read
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
GLP-1s and Hair Loss: Understanding the Link & Treatment Options
The rise of GLP-1 medications for weight loss has brought to light a common side effect: temporary hair thinning. This article delves into why this happens and what you can do about it.
8 min read
Beyond the Scale: Navigating Weight Loss and Appearance Concerns
Significant weight loss, often achieved with medications like GLP-1 agonists, can bring about transformative health benefits but also raises questions about changes in appearance. This article delves into the phenomenon of 'Mounjaro face,' discusses how to approach sensitive conversations about appearance with friends and family, and offers practical advice for maintaining well-being during and after weight loss.
9 min read
GLP-1s Don't Work for Everyone: What to Know If Not Seeing Results
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
7 min read
Shaughna Phillips' Weight Loss Journey: Body Positivity Amid Cellulite & Lipo...
Love Island star Shaughna Phillips is celebrating a 9kg weight loss over four months, sharing transparent before-and-after videos despite cellulite and lipoedema flare-ups. Rejecting Ozempic claims, she credits gym sessions, protein-focused eating, and her Shred It Plan. Her journey emphasizes progress over perfection for busy moms.
6 min read
Lost 9 Stone on Mounjaro: Loose Skin Sparks ElastiK Skin Business
Marc McKee dropped nine stone with Mounjaro, transforming his health but leaving him with loose skin that inspired a new business. ElastiK Skin targets GLP-1 weight loss side effects using peptides, hyaluronic acid, and LED therapy. Early users report better hydration and elasticity with consistent use.
5 min read
GLP-1s Aid Health Even Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
5 min read
Mounjaro Face Effect: Causes and Prevention Tips
The hype around Mounjaro's weight loss results is real, but so is 'Mounjaro face'—sharper yet tired-looking facial changes from rapid fat loss. Dermatologists and surgeons report more patients with hollowed cheeks and sagging skin seeking help. Experts reveal why it occurs and essential prevention strategies focusing on nutrition and skincare.
6 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Genes That Make GLP-1 Drugs Work (or Not): New Study
Why do some people lose remarkable weight on Ozempic while others see minimal results or severe nausea? A new Nature study of nearly 28,000 GLP-1 drug users shows your genes are a key factor. Specific variants in GLP1R and GIPR genes predict both efficacy and side effects, opening doors to personalized prescribing.
5 min read
Genetic Variants May Reduce GLP-1 Diabetes Drug Effectiveness
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
6 min read
Why Ozempic Doesn't Work for Everyone: Hidden Genetic Reason Found
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
5 min read
Hidden Reason Ozempic Fails for Some: GLP-1 Resistance Revealed
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
7 min read
Genetic Mutations Linked to GLP-1 Drug Weight Loss and Side Effects
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
6 min read
Genetic Variations Linked to GLP-1 Weight Loss, Side Effects
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
5 min read
New Study: Why Ozempic Works Better for Some Due to Genetics
Ozempic and similar weight-loss drugs like tirzepatide work better for some patients due to specific genetic variants affecting GLP-1 and GIP receptors, a new 23andMe study shows. While average users lose 10% body weight, those with certain gene copies shed up to 1.5kg more—or face higher nausea and vomiting risks. This research uncovers why responses vary widely.
5 min read
23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss
A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.
4 min read
Alison Hammond Denies Ozempic Use After 11-Stone Weight Loss
TV star Alison Hammond has firmly denied using Ozempic or other weight loss drugs after shedding 11 stone over five years. Motivated by a pre-diabetes diagnosis, she now enjoys an optimum blood sugar range through boxing, weights, and Reformer Pilates. Despite praise for her slim-down, she embraces her size 20 figure: 'I don't want to take up less space in the world.'
5 min read
GLP-1 Drugs: Doctors Urge Exercise and Mental Health Too
GLP-1 medications like Ozempic have transformed weight loss for many, but doctors emphasize they're not a standalone solution. Patient Jelon Smart dropped from 285 to 175 pounds only after adding gym workouts to her regimen. Experts stress combining these drugs with movement, smart eating, sleep, and mental health care for long-term success.
5 min read
Biggest Mistake GLP-1 Users Make, Doctor Says
A surge in GLP-1 drug use has millions turning to shots like Ozempic or pills like Wegovy for weight loss, but doctors warn of a critical error. The biggest mistake? Thinking the prescription is enough without lifestyle changes. A study of 98,000 veterans shows combining GLP-1s with healthy habits slashes cardiovascular risks by 43%.
6 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Taking GLP-1s Like Ozempic? Doctors Urge Exercise and Mental Health Focus
Severe ankle pain led Jelon Smart to Ozempic, where she dropped 30 pounds quickly—but plateaued until adding exercise. Doctors like Dafina Allen and Gerald Onuoha stress that GLP-1s alone aren't enough; movement, mental health, and monitored dosing are key for long-term success and safety.
5 min read
Study: 10% of Wegovy and Ozempic Users See Minimal Weight Loss
Recent trials show about 10% of people using Wegovy and Ozempic experience minimal weight loss, classified as 'non-responders.' Despite average reductions of 15-20%, stories like Samantha Jess's highlight real challenges. Discover why GLP-1 drugs don't work for everyone and how to optimize results.
5 min read
1 in 10 Wegovy and Ozempic Users Lose Less Than 5% Body Weight
Trials show one in ten people on Wegovy and Ozempic lose less than 5% of their body weight, challenging the drugs' reputation as a universal solution. Patient experiences like Samantha Jess's highlight non-responder realities, while experts explain genetic and metabolic factors. Discover why GLP-1 agonists work for some but not others.
6 min read
MGB's New Genetic Risk Calculator for Obesity: A Game Changer
Researchers at Mass General Brigham have launched a revolutionary genetic risk calculator that not only forecasts obesity and Type 2 diabetes but also their long-term health consequences. Powered by data from over 8.5 million participants worldwide, this polygenic risk score outperforms existing tools, especially in diverse populations. Discover why this could enable earlier interventions like GLP-1 medications.
5 min read
Before-and-After Photos Reveal Rebel Wilson's Face Changes After 80-lb Weight...
Side-by-side photos from 2019 and 2025 make Rebel Wilson's facial transformation after shedding over 80 pounds strikingly apparent. Noticeable changes include reduced volume, minor skin elasticity loss in cheeks, neck, and around lips and eyes, plus a sharper jawline. While many attribute it to Ozempic, Wilson clarifies its limited role in her journey.
5 min read
When Weight-Loss Drugs Like Zepbound Don't Work
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
5 min read
Microdosing Ozempic: 67-Year-Old Bobbi Parker-Hall Enjoys Multiple Orgasms
At 67, Bobbi Parker-Hall microdoses Ozempic not for dramatic weight loss, but for metabolic stability and surprising intimacy benefits like multiple orgasms. She shares how low-dose semaglutide, paired with strength training, keeps her lean and vibrant post-menopause. Here's what her story reveals about this trending approach.
5 min read
Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles
At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.
5 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
How $200M Puris Pea Protein Business Fuels Ozempic Generation
As the Ozempic generation ramps up protein intake to support weight loss, Minneapolis-based Puris Proteins has surged to $200 million in revenue as America's top pea protein maker. From basement soybean breeding to supplying giants like Cargill, this family business is powering nutritious habits for GLP-1 users. Here's the story behind their explosive growth.
10 min read
Tanmay Bhat on GLP-1 Drugs Failing Appetite Suppression & Genetic Report
Comedian Tanmay Bhat recently opened up about his disappointing experience with GLP-1 medications, reporting zero appetite suppression despite using them for weight management. He attributes this to a BDNF gene variant affecting satiety signaling, sparking discussions on genetic factors in treatment response. While many see benefits from drugs like semaglutide and tirzepatide, Bhat's story highlights why results vary.
5 min read
Celebs Experiencing 'Ozempic Neck' from Rapid Weight Loss
Hollywood's shift to GLP-1 drugs like Ozempic has led to leaner figures on the red carpet, but some celebs are facing 'Ozempic neck'—loose skin from fast weight loss. This guide explains the phenomenon, its causes, and strategies to manage it. Understand why skin struggles to keep up with GLP-1-induced changes.
5 min read
How GLP-1 Weight Loss Drugs Revolutionized Obesity: Lessons Learned
GLP-1 weight loss drugs such as Wegovy and Zepbound have revolutionized obesity care, leading to up to 20% body weight reduction over 72 weeks. These therapies challenge old views of obesity as mere lifestyle failure, highlighting brain hunger centers, genetics, and hormones. From chronic disease recognition to equitable access, here's how they've reshaped treatment.
5 min read
GLP-1 Drugs & Hair Loss: New Study Reveals Potential Risk
Emerging research is spotlighting a potential link between popular GLP-1 medications like Ozempic and Wegovy and hair loss conditions such as telogen effluvium and androgenetic alopecia. A study of nearly 550,000 patients found a significant association after 12 months of use, even after adjusting for key factors. While benefits for diabetes and weight loss remain strong, awareness and monitoring are crucial.
6 min read
Simon Cowell's 'Ozempic Face' Sparks Fan Speculation
Simon Cowell's latest video before the Britain's Got Talent 2025 finale has fans convinced he's developing 'Ozempic face' due to his noticeably slimmer features and changed eye shape. Social media erupts with comments from 2023 to 2025, even linking him to Ryan Seacrest's look. Despite the buzz, Cowell tells The Sun he's never tried Ozempic.
5 min read
Woman's 39-lb Breasts Won't Stop Growing: Gigantomastia Discovered on Mounjaro
A 30-year-old woman from East Anglia discovered her rare gigantomastia condition—causing her breasts to weigh 39 lbs.—while losing weight on Mounjaro. Despite rapid breast growth amid overall weight loss, she faces numb arms, scarring, and breathing issues. Her story highlights the unexpected challenges of GLP-1 medications like tirzepatide.
5 min read
Ozempic Weight Loss: Celebrity Rumors vs. Real Science
When Bollywood star Tamanna Bhatia appeared slimmer, social media buzzed with Ozempic accusations, sparking debates on beauty standards and rapid weight loss. Beyond the rumors, Ozempic (semaglutide) is a powerful GLP-1 drug transforming weight management. This guide dives into the science, risks, and healthier paths forward.
5 min read
GLP-1 Drugs: Gastroparesis Risks, Lawsuits & Management Guide
GLP-1 medications like Ozempic and Wegovy have transformed weight management, but reports of gastroparesis and bowel issues have sparked lawsuits. This guide breaks down the science, risks, and practical steps for patients. Learn how to balance benefits with safety through informed strategies.
4 min read
GLP-1 Pancreatitis Risk: MHRA Warning and Patient Guide
The UK's MHRA has updated guidance on a small but serious risk of acute pancreatitis linked to popular GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. With over 1.6 million users, understanding symptoms and reporting is crucial. This guide breaks down the latest data, risks, and management strategies.
4 min read
Tirzepatide vs Semaglutide: Weight Loss Duration After Stopping
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
4 min read
GLP-1 Long-Term Use: Regain Risks, Costs & Alternatives
GLP-1 medications like Ozempic and Wegovy promise dramatic weight loss, but new studies reveal a catch: most users regain weight within 1-2 years of stopping. High costs and side effects add to the burden, prompting interest in permanent alternatives. Learn the facts to make informed choices for your metabolic health.
4 min read
Mounjaro Weight Regain: Why It Happens Fast & How to Fight It
Many users like the author experience devastating weight regain shortly after stopping Mounjaro, mirroring real-world and trial data. This guide unpacks the physiology, backed by studies, and offers practical steps to sustain your progress. Don't let hard-won losses slip away—arm yourself with knowledge.
5 min read
GLP-1 Revolution: Ozempic, Wegovy, Mounjaro Rise
GLP-1 injections like Ozempic, Wegovy, and Mounjaro have exploded from niche diabetes therapies to cultural icons in weight management. While offering profound metabolic benefits, their rapid mainstreaming raises questions about proper use, side effects, and societal pressures. This guide unpacks the science, real-world stories, and future implications.
4 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
4 min read
Oprah discloses how GLP-1 drugs resulted in her sobriety
Media mogul Oprah Winfrey has openly discussed her use of GLP-1 drugs for shedding pounds, but she recently shared a surprising outcome: the end of her alcohol consumption. This change has revitalized her sense of vitality and openness, while offering insights into obesity and personal growth. She encourages others to embrace available options without self-blame.
2 min read
Cleveland Clinic Reverses Type 2 Diabetes Using AI, Not GLP-1 Drugs
The Cleveland Clinic is utilizing an AI-powered approach to reverse type 2 diabetes. This innovative method focuses on creating a 'digital twin' of a patient's metabolism, leading to significant improvements in health markers and a reduction in medication dependence.
10 min read
I Thought GLP-1 Skincare Was a Gimmick -- I Was Mistaken
The rise of GLP-1 drugs has sparked interest across various industries, including beauty. While some claims may seem like clickbait, the need for skincare innovation to address skin changes related to these medications is real. Experts and research suggest GLP-1 skincare is a legitimate response to these changes.
8 min read